 | Up a level |
Liu, Jinxia; MacNaughtan, Jane; Kerbert, Annarein J C; Portlock, Theo; Martínez Gonzalez, Javier; Jin, Yi; Clasen, Frederick; Habtesion, Abeba; Ji, Huoyan; Jin, Qin; Phillips, Alexandra; De Chiara, Francesco; Ingavle, Ganesh; Jimenez, Cesar; Zaccherini, Giacomo; Husi, Katherine; Rodriguez Gandia, Miguel Angel; Cordero, Paul; Soeda, Junpei; McConaghy, Lynda; ... (2024). Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis. (In Press). Gut BMJ Publishing Group 10.1136/gutjnl-2023-330699
Peyvandi, Flora; Scully, Marie; Kremer Hovinga, Johanna Anna; Cataland, Spero; Knöbl, Paul; Wu, Haifeng; Artoni, Andrea; Westwood, John-Paul; Mansouri Taleghani, Magnus; Jilma, Bernd; Callewaert, Filip; Ulrichts, Hans; Duby, Christian; Tersago, Dominique (2016). Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. New England journal of medicine NEJM, 374(6), pp. 511-522. Massachusetts Medical Society MMS 10.1056/NEJMoa1505533
Cataland, Spero R; Peyvandi, Flora; Mannucci, Pier M; Lämmle, Bernhard; Kremer Hovinga, Johanna A; Machin, Samuel J; Scully, Marie; Rock, Gail; Gilbert, James C; Yang, Shangbin; Wu, Haifeng; Jilma, Bernd; Knoebl, Paul (2011). Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. American journal of hematology, 87(4), pp. 430-2. New York, N.Y.: Wiley-Liss 10.1002/ajh.23106
